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CHARACTERIZING PARKINSON'S DISEASE
In a classic monograph, "An Essay on the Shaking Palsy," published over 175 years ago, the London phy sician, James Parkinson (1817), frrst described a "series" of six patients suffering from the movement disorder which came to bear his name. In an age when physical examinations had not yet been developed as a basis for diagnosis, his astute observations and graphic descrip tions were sufficiently detailed to make the diagnosis inescapable. His characterization of its insidious onset, "that it rarely happens, that the patient can form any recollections of the precise period of its commence ment," of "a slight sense of weakness, with a prone ness to trembling in some particular part ... most com monly in one of the hands or arms" is still the best description of the earliest symptoms of Parkinson's dis ease. "Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported: with a propensity to bend the trunk for ward, and to pass from a walking to a running pace: the senses and the intellect being unimpaired" was his summary of the characteristic features of Paralysis Agi tans. lts inexorable progression so that "the tremulous motion of the limbs occur during sleep and augment until they overwhelm the patient, and frequently with much agitation and alarm" and the ultimate helpless ness, "the power of conveying the food to the mouth is at length so much impeded that he is obliged to con sent to be fed by others," are strikingly portrayed.
During the remainder of the 19th century, addi tional features of the disease were described. As phys ical examinations became part of the study of patients, muscular rigidity and "cogwheeling" were noted by Trousseau (1867) . The great French neuropathologist and neurologist, Jean-Martin Charcot, delineated the "pill rolling" parkinsonian tremor from other causes of tremor. He also noted that the patients were not weak, that some may have little or no tremor, and that ab sence of facial expression (masked facies) is a striking feature of the disorder (Charcot 1871; Goetz 1986 ). Char cot deemed inappropriate the terms "paralysis agitans" or "shaking palsy" and it was he who named the disor der Parkinson's disease.
Although the clinical characteristics were well de scribed, pathological features of Parkinson's disease were not defIned clearly until the 20th century and many, including Charcot, considered the disorder to be "functional," that is, a neuropsychiatric disorder. At the beginning of this century, Lewy (1913) Tretiakoff (1919) that depigmentation of the substantia nigra is a consistent feature of parkin sonism. Loss of the neurons in this area then became recognized as characteristic of parkinsonism, whether the disorder was a result of viral infection, exposure to toxins, anoxia, or from unknown causes. Only 40 years ago, however, it was thought that "in view of widespread changes elsewhere in such cases it is difficult to relate the Parkinsonian syndrome to a lesion located in one situation" (Brain 1951).
EMPIRICAL TREATMENT OF PARKINSON'S DISEASE
The frrst pharmacotherapy for Parkinson's disease Will introduced over a century ago by Orden stein (1867). Belladonna alkaloids were administered as a means for controlling the annoying drooling described by Parkin son, "the saliva fails of being directed to the back part of the faucies and hence is continually draining from the mouth." Unexpectedly, the drugs also improved the movement disorder. AI though the benefIcial effects are only modest (20% to 30%) and are obtained in only some (60% to 80%) of the patients, they remained the mainstay of antiparkinsonian medication for over four generations. To obtain greater specifIcity in controlling rigidity and tremor and to reduce undesirable side effects, synthetic anticholinergic drugs, such as benz tropine mesylate (Cogentin) and trihexylphenidyl (Ar tane), were introduced about 70 years later (Corbin 1949; Dorshay et al. 1949) . It is generally accepted that these drugs act at muscarinic receptors in the striatum, presumably to balance excessive cholinergic activity, but even with current advances in our understanding of the striatal neurotransmitters and neuronal pathways, the exact mechanism of these drugs remains uncertain. Amphetamine had also been found to reduce rigidity (Solomon et al. 1937 ) and benadryl, an antihistamine with some anticholinergic effects, had been recommend ed (Budnitz 1948) . Apomorphine, a drug that was best known as an emetic, serendipitously was found to be of use in parkinsonism (Schwab et al. 1951) . With ad vances in our understanding of basal ganglia function, the basis for efficacy of these agents has become clearer.
SURGICAL TREATMENT OF PARKINSON'S DISEASE
The clinical observation that after a cerebrovascular ao cident, parkinsonian tremors become arrested on the side with hemiplegia led to the notion that surgical le sions of the brain might be useful in treating Parkin son's disease. However, early trials showed that lesions in the cortex or descending pyramidal tracts arrested tremor only at the expense of paralysis. Other attempts II surgical treatments were also generally unsuccess fuluntil Cooper (1961) accidentally discovered that li plion of the anterior choroidal artery abolished par kinsonian tremor and rigidity without causing paralysis. Subsequent studies defmed clinical criteria for accep tance for surgery and described the speci&c regions to be targeted to alleviate tremor or rigidity (Cooper 1965) . The advent of levodopa treatment, however, eclipsed further exploration of the surgical approaches to treat mtnt ofParkinson's disease. Recently, however, neu lIlSurgical approaches have become increasingly prom ling in having a role in the treatment of this movement disorder.
DOPAMINE AND RATIONAL TREATMENT OF PARKINSON'S DISEASE
The introduction of a rational treatment of Parkinson's diease and our current understanding of the patho physiology of parkinsonian syndrome are attributable �the re markable advances in the neurosciences that ltave occurred during the last 35 years. In 1958, Carls lDnand others (Carlsson et al. 1958; Bertler and Rosen pm 1959) showed that dopamine was present in the m, with highest concentrations in the striatum. They lImtonstrated, in mice and in rabbits, that brain dopa line is depleted by reserpine, and that administration .3,4-dihydroxyphenylalanine (DOPA) dramatically IrYtrses reserpine-induced tranquilization, Parkinson It motor defIcits, and ptosis. They showed also that pmreatment with a monoamine oxidase (MAO) inhib bpotentiated DOPA in reversing reserpine effects. These observations and the uneven distribution of atecholamines in brain suggested that these amines llaction as neurotransmitters and that dopamine is in valved in control of motor activity. Several years later, trgreatly red uced (to about one tenth normal) con CBltrations of dopamine in the caudate, putamen, and IIIbs tantia nigra of brains from parkinsonian patients ns reported (Ehringer and Hornykiewicz 1960) . Shortly thereafter, by use of the newly developed liItotIuores cence techniques to visualize catechola IIiIes in neurons and their processes, various catechol Cllin ecell groups were identifIed and their projections _nstrated (And en et al. 1964 ; Lindvall and Bjork bnd 1%4). The previously unknown nigrostriatal &pa!nine-containing tract, with cell bodies in the sub IIIn tia nigra pars compacta (SNc) and axonal projec6Ins to the striatum, explained the relationship be IIIftn neuron loss in the SNc and dopamine depletion In the striatum.
Invited Lecture 3
These observations were seminal to understand ing the pathophysiology of parkinsonian syndromes and encouraged attempts to pharmacologically replace the missing neurotransmitter. Because it was known that dopamine does not penetrate the blood-brain bar rier but that DOPA, its amino acid precursor, reversed the behavioral effects of reserpine and elevated brain dopamine levels, it was apparent that this amino acid readily enters the brain and is decarboxylated (Fig. 1) . Initial efforts at dopamine substitution with DOPA failed because of severe side effects, particularly nau sea and vomiting. However, by gradually increasing the doses of DOPA and thereby avoiding or reducing adverse side effects, Cotzias et al. (1967 Cotzias et al. ( , 1969 succeeded in administering high doses of DOPA and achieved remarkable symptomatic improvement. It appeared that Parkinson's disease was mostly a result of dopa mine de&ciency. Although other biochemical abnormal ities, such as diminished levels of serotonin, norepi nephrine, gamma-aminobutyric acid (CABA) and glutamate decarboxylase, have been found in brains of parkinsonian patients, the de&ciencies are not as strik ing as the loss of dopamine. The physiologic isomer of DOPA, levodopa, was introduced and strategies were then focused on enhancing the efficacy of levodopa treatment. Levodopa administered orally must pass from the lumen of the intestine into the hepatic and systemic cir culations. Entry into the brain parenchyma requires transfer from blood through the endothelial cells lin ing the capillaries. Because considerable amounts of the decarboxylating enzyme, aromatic amino acid decar boxylase (AADC), are present in the intestinal wall, the liver, the kidneys, and the brain capillary endothelium, a good deal of the administered levodopa can be de car boxylated at these sites. Selective inhibition of ex tracerebral AADC was therefore explored as a means for enhancing levodopa efficacy. Two AADC inhibitors, carbidopa and benserazide, were found that could be administered in doses that affect only extracerebral AADC (including that of the brain capillaries) and were shown to be useful adjuncts to levodopa treatment (Papavasiliou et al. 1972; Pletscher 1973; Pinder et al. 1976) . These drugs increase bioavailability of levodopa by enhancing levodopa absorption from the intestine, preventing its decarboxylation in the peripheral tissues and inactivating the brain capillary enzymatic barrier to levodopa. A similar strategy, using new inhibitors of catechol-a-methyl transferase, an enzyme involved in the metabolism of catechols ( Fig. 1) is currently be ing explored as a means for potentiating dopamine andlor a levodopa sparing effect.
The antiparkinsonian effects of levodopa are gener ally stable and reasonably predictable for the &rst sev eral years, but after some time, dyskinesias, fluctuations in efficacy ("on-off responses" and "wearing off"), freezing, mental changes, and loss of efficacy (requir ing higher levodopa doses and inviting more side effects) emerge. Mechanisms that have been cited as contributing to these adverse effects include progres sion of the disease with diminished decarboxylation of levodopa to dopamine in brain, inability to regulate ex tracellular dopamine concentration by uptake into dopaminergic terminals, alterations in levodopa phar macokinetics, and changes in dopamine receptor sen sitivity and responsivity. On the basis of these hypoth e::;es, during the 1970s and 1980s, several strategies were explored to restore levodopa efficacy and to avoid ad verse effects. Dosages and times of levodopa adminis tration were manipulated, slow release formulations or continuous intravenous infusions to stabilize levodopa plasma levels, and drug "holidays" to allow for normali zation of dopamine receptors and potentiation were ex plored and prolongation of the effects of dopamine was attempted by inhibiting MAO. Although some im provements in symptomatic management were ob tained, none of these modi&cations of levodopa ther apy have been universally satisfactory. The common NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 failures encountered with long-term levodopa treat ment encouraged exploration of alternatives to levodopa.
Alleviation of dopamine de&ciency by fInding other means of stimulating dopamine receptors seemed feasi ble. It was recognized that the parkinsonian side effects of some antipsychotic drugs might be related to block ade of dopamine receptors and reasoned that stimula· tion of these receptors would reverse parkinsonian symptoms.
DOPAMINE RECEPTOR AGONISTS
Dopamine receptor agonists and antagonists were frr st discovered because of their ability to evoke or block b e· havioral or endocrine effects associated with dopamine. Some ergot derivatives, for example, bromocryptine, were found to inhibit prolactin secretion, whereas drugs that depleted dopamine (reserpine) or had antipsy· chotic effects (chlorpromazine) enhanced prolactin secretion. When it appeared that dopamine agonists might be useful in treating Parkinson's disease, several ergot derivatives were tested and found to be e ff ect i ve. The actions of these drugs (e.g., bromocriptine, lisu· ride, pergolide) are not identical, and they do notmimie dopamine precisely, presumably because they eac h i n· teract differently, from dopamine and from each other, with dopamine receptor subtypes.
Dopamine Receptor Subtypes
Nearly 15 years ago, dopamine receptors were ciassmed into two subtypes (Kebabian and Caine 1979); stimula· tion of D1 receptors activated adenylcyclase and thereby enhanced cyclic adenosine monophosphate (AMP) production, whereas stimulation of D2 rece p tors failed to affect adenylcyclase or even diminished cyclic AMP formation. Subsequent demonstration of two types of binding sites for radioactively labeled dopa mine agonists and antagonists con&rmed the division of dopamine receptors into at least two categories. The demonstration in brain of anatomically distinct b in d · ing sites for radioactively labeled dopamine agon i sts and antagonists further supported the division of dopa mine receptors into at least two categories (Young and Penney 1989) . The distinction between the two su b types of dopamine receptors also made possible the c h arac· terization of dopamine agonists with regard to t h e i rae· tions at these receptors subtypes. Dopamine D2 recep tor stimulating properties appear to be important for antiparkinsonian effects; however, there are signifIcant D1-D2 synergistic interactions so that drugs t h at have some degree of 0 1 agonist activity have some a d van tages. Within the last 3 years, not only have t h e D 1 an d 0 2 receptor subtypes been cloned (Bunzow et IIId thalamocortical) constitute direct cortical-subcor bkortical circuits (Fig. 2) ; the two inhibitory synapses arount for disinhibition and activation of descending IIOtor neurons. There is another, parallel GABAergic projection from the striatum to the external layer of the JIobus pallidus (GPe). The GABAergic neurons from IheGPe inn ervate glutaminergic excitatory neurons in lhesubthalamic nucleus. The subthalamic neurons in lIftVate GABAerigc neurons in the GPi and thus pro file an alternative, indirect, ti.ve-neuron cortical IIbcortical-cortical circuit (Fig. 2) ; the three inhibitory IJIIa pses have a net inhibitory effect, inhibiting disin limon. Smooth and efti.cient motor control requires mordination and balance of the output of these oppos "pathways attained by modulatory mechanisms that
• only beginning to be understood in terms of the or pnization and special characteristics of subpopulations The complexity of interconnections via neuronal net works, feedback circuits, and 0 1-0 2 receptors on the same cell defIes simple analysis, but it is evident that the net effects of dopamine defIciency produce parkin sonian symptoms. Release of dopamine by ampheta mine, the action of apomorphine on dopamine recep-tors, and the action of amantidine on dopamine disposition probably explain their antiparkinsonian affects. During the last 20 years the neuroanatomic and pharmacologic basis for symptomatic treatment of par kinsonian syndromes by dopamine and dopamine agonists has become better understood. Although ini tially effective, levodopa has well-recognized limita tions; improvements in therapy are still required to con trol symptoms after levodopa failure. Prevention or arrest of the degenerative process, not addressed by symptomatic treatments, is receiving increasing at tention.
DISCOVERY OF A TOXIN THAT CAUSES PARKINSONISM
Approximately 10 years ago, a neurotoxin that was des tined to change the focus of Parkinson's disease research was fIrst recognized. The fIrst reported case of parkin sonism resulting from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was that of a 23-year-old student who was referred to the National Institutes of Health (NIH) because of a history of multiple drug abuse and the rapid development of severe parkinsonism (Davis et a1. 1979 ). The young man had synthesized on several occasions alphaprodine, an analogue of de merol, which he had used intravenously, often with cocaine. Carelessness in synthesis and purifIcation resulted in production of a side reaction product, MPTP, which was a major component of the impure demerol analogue. After several daily self-administered doses of the impure narcotic, he was found mute and immo bile. The initial diagnosis of catatonic schizophrenia resulted in hospitalization in a mental institution, but his striking rigidity subsequently led to a suspicion of severe parkinsonism; this was confIrmed by success ful treatment with L-DOPA/carbidopa and the patient was referred to NIH. After admission, the history of drug synthesis and use was elicited and the components of the drug mixture discovered. The motor defIcits were indistinguishable from Parkinson's disease, and his cerebrospinal fluid levels of homovanillic acid, the ma jor metabolite of dopamine, were markedly lower than normal, consistent with the clinical diagnosis. After dis charge, he continued abusing drugs and was found dead from an overdose of cocaine and demero1. Exami nation of the brain showed severe degeneration of the nigrostriatal neurons, neurochemical evidence of do parninergic defIcit, and a single eosinophilic body in the region of the substantia nigra.
Administration to rats, rabbits, or guinea pigs of MPTP, its precursor or alphaprodine, alone or in com bination, failed to produce a toxic motor defIcit . Several years after the initial case, there sur faced in California a cluster of patients with toxic par-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 kinsonism due to MPTP (Langston et al. 1983 ), also ap· parently as a result of an attempted illicit synthesis of alphaprodine.
With the knowledge of the resistance of rodents to toxicity of MPTP, the compound was now administered to rhesus monkeys, and these animals were found to be vulnerable to the toxin (Burns et al. 1983) . Daily in travenous administration of several relatively small doses of MPTP was followed by the rapid development over a few days of stooped posture, marked brady cardia, tremor, and rigidity. Initially, there were marked decreases in the cerebrospinal fluid levels of homovanil lic acid, 3-methoxy-4-hydroxyphenylglycol, and 5-hy droxyindoleacetic acid, the major metabolites of dopa· mine, norepinephrine, and serotonin, respectively, but only the levels of homovanillic acid remained low after 1 month. All of the motor defIcits were reversed tem porarily by the administration of L-DOPA. When the brains of these animals were examined, there was al most complete destruction of the neurons in the sub stantia nigra and marked depletion of dopamine in the striatum. Other brain regions with dopaminergic or noradrenergic neurons were relatively unaffected by the toxin. Thus MPTP appeared to specifIcally target dopaminergic neurons of the nigrostriatal pathway. A similar parkinsonian syndrome in squirrel monkeys (Langston et a1. 1984) , marmosets (Jenner et al. 1984) , and other primate species was found to be caused by MPTP _ Although rats, guinea pigs, rabbits, and gerbils appear to resist MPTP toxicity, when administered repeatedly in high doses, mice were found to be vul nerable to the toxin; but in mice, both noradrenergic neurons and dopaminergic neurons throughout the brain as well as the nigrostriatal neurons are affected (Hallman et al. 1984; Heikkila et a1. 1984) . The mouse, however, has been widely used to examine the mecha nisms of MPTP toxicity. The discovery that I-methyl-4-phenylpyridinium (MPP+) is formed and retained in the brains of monkeys treated with MPTP (Markeyet al. 1984) suggested that biotransformation (Fig. 3) of the administered compound to its oxidized metabolite was important for toxicity_ High concentrations of MPP+ found in regions of brain which escape exten sive damage indicate that dopaminergic neurons of the SNc are peculiarly vulnerable to the toxic effects of MPP+ . Conversion of MPTP to MPP+ is mediated by MAO type B. Rat brain mitochondria were found to ox idize MPTP to MPP +, and the oxidation was found to be prevented by deprenyl, a specifIc MAO-B inhibitor, but not by clorgyline, a specifIc MAO-A inhibitor (Chiba et al. 1984) . In monkeys, pretreatment with pargyline, a nonspecifIc MAO inhibitor, or deprenyl prevents both the accumulation of MPP+ and the toxic effects of MPTP (Markey et a1. 1984; Langston et a1. 1984b; Co hen et al_ 1985) . In mice also, pretreatment with inhibi tors of MAO prevents striatal dopamine depletion (Fig. 3) . Syn iplosomes prepared from rat striatum (Javitch and Snvder, 1984) or cortex (Javitch et al. 1985) accumulate lH:MPP+, but not 3H-MPTP. The uptake of 3 H-MPP+ 11)' striatal synaptosomes is blocked by inhibitors of dopamine uptake, and with potencies which are well corre lated with blockade of dopamine uptake. Also, the potencies of several drugs in blocking cortical synapto some 3H-norepinephrine uptake are similar to their potencies in blocking 3H-MPP+ uptake. In mice, those drugs that block norepinephrine transport protect The currently favored hypothesis for molecular ba sis for MPP+ toxicity is inhibition of mitochondrial respiration (Singer and Ramsay 1990; Kopin 1992) . In addition to its accumulation by amine transporters in dopaminergic neurons, MPP+ is further concentrated into mitochondria where it inhibits the electron trans port at complex I. This interference with energy me tabolism and the possible enhanced generation of free radicals as a result of partial reduction of oxygen is be lieved to cause the cell damage and to disrupt vital processes essential for cell survival.
The attention attracted by the discovery of MPTP and its mechanisms of toxicity has had an enormous influence on the directions of research on Parkinson's disease. Recognition and understanding of the mecha nisms of toxicity of MPTP provided clues as to the pathogenesis of Parkinson's disease, and the availabil ity of so faithful an animal model of human parkin sonism has opened opportunities for exploration of new therapies and approaches to preventing or arresting the degenerative process.
FOCUS ON PATHOGENESIS AND NEUROPROTECTION
Although the primary cause of Parkinson's disease is unknown, a number of clues have suggested that a com bination of hereditary and environmental factors may affect survival of dopaminergic neurons.
Environmental Neurotoxins
The occurrence of MPTP-induced parkinsonism in at least one chemist who had synthesized large quanti ties of the compound (Burns et al. 1985) proved that it was possible that sporadic cases of Parkinson's dis ease could result from exposure to an environmental toxin. Extensive searches for environmental or endog enous toxins have yielded provocative epidemiologic evidence in support of a neurotoxin in the environment (Tanner and Langston 1990) , but no such toxins have been identified.
Oxidative Stress
Exploration of the processes involved in MPTP toxicity rekindled interest in previously proposed mechanisms of nigrostriatal degeneration. Oxidation of catechola mines, whether by autoxidation of the catechol moie ties to hydroquinones or quinones, or by enzymatic ox idative deamination results in the formation of reactive oxygen species (superoxide anion, hydroxyl radical, and hydrogen peroxide). Transitional metals such as manganese and iron catalyze the transfer of electrons NEUROPSYCHOPHARMACOLOGY 1993 -VOL. 9, NO.1 during the partial reduction of oxygen, and the coinci dence of high dopamine and iron contents in the SNc has encouraged hypotheses linking free radical forma tion with Parkinson's disease (Graham 1984; Cohen 1985) . Considerable evidence has been accumulated to support the view that oxidative stress and free radical formation catalyzed by iron might play an important role in the pathogenesis of Parkinson's disease (Jenner 1991) . When dopamine release is enhanced, levels of oxidized glutathione increase; this index of oxidative stress attending dopamine release can be prevented by pretreatment with an inhibitor of MAO-B (Cohen and Spina 1989) . Increased lipid peroxidation in the sub stantia nigra of parkinsonian patients (Dexter et a1. 1989) , supports the notion that free radicals have damaged the dopaminergic neurons in the nigrostria tal pathway. Particular vulnerability of the SNc to ox idative stress may result from deficiencies in protective mechanisms. Levels of superoxide dismutase are re ported to be elevated, whereas levels of glutathione and glutathione peroxidase have been reported to be abnor mally low in the substantia nigra of Parkinson's disease patients (Saggu et al. 1989; Perry and Yong 1986) . Con version of superoxide and hydrogen peroxide to the highly reactive hydroxyl ion (Haber-Weiss reaction) is normally slow, but in the presence of iron, the reaction is rapid. Post-mortem levels of iron, particularly ferric ion, are increased in the substantia nigra of parkinso nian patients (Sofic et al. 1991; Dexter et al. 1991) , but the iron appears to be deposited in astrocytes, macro phages, reactive glia, and nonpigmented neurons (Hirsch et al. 1991) . Thus, although there appears to be increased iron deposited in the substantia nigra of parkinsonian patients, it is unclear if this is a result of the neuronal degeneration or due to an abnormality in iron metabolism.
Selectivity of MPTP and of the degenerative pro cess in Parkinson's disease for melanin-containing neu rons suggests that conditions that predispose to mela· nin formation may be responsible for vulnerability of these cells to the degenerative process, or that neu· romelanin plays a role by producing free radicals or by storing a neurotoxin that is slowly released and has a more prolonged toxic effect on the cells in which it is stored. Neuromelanin is a complex redox polymer that contains free radicals; it has also been proposed that neuromelanin-iron interactions might account for the vulnerability of pigmented neurons to oxidative stress (Ben-Shachar et al. 1991) .
Mitochondrial Abnormalities
Deficiencies in mitochondrial electron transport simi lar to those caused by MPP+ have been reported in of parkinsonian patients, but it is claimed that the mi tochondrial defect is confmed to the substantia nigra Deprenyl (selegiline) and/or tocopherol were ad ministered to previously untreated parkinsonian pa tients and deprenyl, with or without tocopherol, was found to signifIcantly delay the onset of disability sufbcient to warrant initiation of levodopa therapy (The Parkinson Study Group 1989) . Although the fIndings were dram atic, whether they were the result of symp tomatic improvement due to potentiation of endoge nous dopamine (by any of several potential mecha nisms) or a really neuroprotective effect is the subject at considerable controversy (see Olanow and Caine 1992) , particularly since treatment with deprenyl did not produce any signifIcant biochemical changes to sub stantiate a free radical scavenging effect (Baronti et al. 
1992).
In monkeys, systemic administration of MK-801, lcompetitive antagonist for the N-methyl-D-aspartate receptor, has been reported to prevent the development lithe parkinsonian syndrome induced by MPTP, al though the brain levels of MPP+ were higher than in lIIO nkeys receiving MPTP alone (Zuddas et al. 1992 ).
Hexcitotoxins play a signifIcant role in the degenera- planted into the striatum were found to reinnervate part of the previously denervated striatum and to restore dopamine turnover and release to near-normal levels.
In both rats and monkeys, fetal nigral grafts reverse, at least in part, parkinsonian symptoms (Lindvall 1991).
Although autologous adrenal medullary grafts in pa tients with Parkinson's disease had been reported to (Bankiewicz et a1. 1991) . In that study, implant-induced improvement was stable for up to 6 months and post-mortem exami nation revealed sprouted dopaminergic fIbers. The fIbers appeared to be derived from dopamine neurons surviving in regions less affect by MPTP, suggesting that implant-induced and trophic factor-mediated dopaminergic sprouting by the host brain neurons could play a role in the behavioral recovery and clinical improvement seen in parkinsonian patients after brain implants.
It is clear that further work is necessary to estab lish the mechanisms of the effects and to optimize the transplantation procedure. It is possible that cells ge netically engineered to produce dopamine or neuro trophic factors will prove to be of use in replacing dopa mine, restoring dopaminergic innervation or arresting progression of the degenerative process.
Summary
The saga of research on Parkinson's disease begins with astute clinical observation and includes a pandemic of encephalitis and toxin-induced parkinsonism in young chemists and drug abusers. These tragic events pro vided incentives and clues for progress in understand ing parkinsonism from all causes. The remarkable advances in the neurosciences have contributed enor mously to elucidating the pathophysiology of the dis order and have provided the basis for the introduction of levodopa, the &rst rational treatment of a disorder of the central nervous system. Newer understandings of the role of growth and of neurotrophic factors, of ox idative stress, and of molecular biology, as well as use of brain tissue implants as means for treatment of Par kinson's disease, are pacing the advances in the excit ing search for means of preventing and arresting the progression as well as providing symptomatic treatment of degenerative diseases of the nervous system.
